Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03438266 · ClinicalTrials.gov registry record · NA
A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula
A NA study, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT03438266 is a NA study that has completed, run by Allergan. The registered enrollment target is 66 participants.
The verdict
NCT03438266, a NA study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM VOLUMA® XC injectable gel using cannula in participants seeking correction of age-related volume deficit in the mid-face.
Interventions
- DEVICE JUVÉDERM VOLUMA® XC injectable gel with cannula
- DEVICE JUVÉDERM VOLUMA® XC injectable gel with needle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2018-02-05 |
| Est. Completion | 2018-08-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03438266
The ClinicalTrials.gov registry entry for NCT03438266 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JUVÉDERM VOLUMA® XC injectable gel with cannula is the first listed.
NCT03438266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03438266 about?
NCT03438266 is a clinical study titled "A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula". The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM VOLUMA® XC injectable gel using cannula in participants seeking correction of age-related volume deficit in the mid-face.
What is the current status of trial NCT03438266?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2018-02-05. Estimated completion is 2018-08-02.
What interventions are being tested in trial NCT03438266?
The interventions under investigation include: JUVÉDERM VOLUMA® XC injectable gel with cannula (DEVICE), JUVÉDERM VOLUMA® XC injectable gel with needle (DEVICE).
Who is sponsoring clinical trial NCT03438266?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.